

- Hyperkalemic periodic paralysis (HyperKPP) (*Cont.*):  
 genetic testing for, 450t  
 secondary, 310  
 treatment of, 462e-18
- Hyperkinetic movement disorders, **2618**, 2619t  
 chorea. *See* Chorea(s)  
 drug-induced, 2624  
 dystonia. *See* Dystonia  
 hemiballismus, 2623  
 myoclonus. *See* Myoclonus  
 paroxysmal dyskinesias, 2624–2625  
 restless legs syndrome. *See* Restless legs syndrome  
 tics, 2623  
 Tourette's syndrome, 2623  
 tremor. *See* Tremor
- Hyperleucine-isoleucinemia, 434e-3t
- Hyperlipidemia. *See* Lipoprotein disorders
- Hyperlipoproteinemia, type III (familial dysbetalipoproteinemia), 2440t, 2443
- Hyperlysinemia, 434e-3t
- Hypermagnesemia, **2462**  
 AV conduction block in, 1471t  
 clinical features of, 463e-4, 2463  
 etiology of, 2462–2463, 2463t  
 inpatient neurologic consultation for, 463e-4  
 treatment of, 2463
- Hypermetabolic state, **460**, 460t
- Hypermethioninemia, 434e-2t
- Hypernatremia, **303**  
 clinical features of, 303  
 diagnosis of, 303–304, 303f  
 etiology of, 64e-3–4, 303, 463e-3  
 free water deficit in, 64e-4  
 hypodipsic. *See* Hypodipsic hypernatremia  
 inpatient neurologic consultation for, 463e-3  
 with parenteral nutrition, 98e-7t  
 treatment of, 302t, 304
- Hyperopia, 195
- Hyperornithinemia, 434e-3t, 435e-1t
- Hyperosmolality, 463e-3
- Hyperostosis corticalis generalisata (van Buchem's disease), 426e-5
- Hyperoxaluria, 434e-2t, 1868, 1943
- Hyperoxic preconditioning, 477e-1
- Hyperparathyroidism  
 anemia in, 630  
 familial isolated, 2340  
 global considerations in, 315  
 muscle weakness in, 462e-19  
 prevalence of, 2254t  
 primary, **2470**  
 asymptomatic, 2470, 2472, 2473t  
 clinical features of, 2472–2473  
 diagnosis of, 2472, 2473, 2473f, 2479  
 etiology of, 2470  
 genetic considerations in, 2471–2472, 2471f  
 incidence of, 2470  
 in MEN syndromes. *See entries at* Multiple endocrine neoplasia  
 natural history of, 2470  
 pathology of, 2470–2471  
 treatment of, 2473–2475, 2473t  
 screening/testing for, 2254t  
 secondary, 314t, 1815, 2478–2479  
 tertiary, 2479
- Hyperparathyroidism-jaw tumor (HPT-JT) syndrome  
 clinical features of, 2342  
 genetic considerations in, 2337t, 2342, 2470, 2472  
 screening tests in, 2343t  
 treatment of, 2342
- Hyperparathyroid-like syndromes, 2475, 2476f
- Hyperpathia, 89–90, 158, 2643
- Hyperperfusion states, 463e-1–2, 463e-1t, 463e-2f
- Hyperphagia, 2264
- Hyperphenylalaninemia, 434e-1, 434e-2t
- Hyperphosphatemia, **2460**  
 in acute kidney injury, 1808, 1810  
 in chronic kidney disease, 1815, 2485  
 clinical features of, 2461
- etiology of, 2460–2461, 2461t  
 hypocalcemia and, 2487  
 with parenteral nutrition, 98e-7t  
 severe acute, 2487  
 treatment of, 2461
- tumoral calcinosis in, 426e-8  
 in tumor lysis syndrome, 1795
- Hyperpigmentation, **359**  
 in adrenal insufficiency, 2324, 2326f  
 diffuse, 360–361, 360t  
 drug-induced, 361, 379  
 localized, 359–360, 360t  
 in Whipple's disease, 1093
- Hyperplastic polyp, 537
- Hyperprolactinemia, **2266**  
 clinical features of, 2266–2267  
 cocaine use and, 469e-1  
 diagnosis of, 328, 2267  
 erectile dysfunction in, 326  
 etiology of, 2266, 2266t, 2339  
 galactorrhea and, 2267  
 hirsutism in, 332  
 hypogonadotropic hypogonadism and, 2365  
 laboratory investigation of, 2267  
 prevalence of, 2254t  
 screening/testing for, 2254t  
 treatment of, 2267
- Hyperproliferinemia, 434e-2t
- Hyperpyrexia, 124, 126
- Hyperreactive malarial splenomegaly, 1374–1375
- Hypersensitivity myocarditis, 1562
- Hypersensitivity pneumonitis, **1681**  
 clinical features of, 1682  
 clinical prediction rule, 1683  
 definition of, 1681  
 diagnosis of, 1682–1683, 1682f, 1683f, 1711t  
 differential diagnosis of, 1683  
 etiology of, 1681, 1681t, 1691  
 global considerations in, 1683  
 pathophysiology of, 1682  
 treatment of, 1683
- Hypersensitivity reactions. *See also* Anaphylactic reactions  
 to contrast agents. *See* Contrast agents  
 delayed-type, 372e-29–30, 377–378, 1107  
 drug-related. *See* Drug-induced hypersensitivity syndrome (DIHS); Drug-induced illness  
 to human antibodies, 1796  
 immediate-type, 372e-29, 2115  
 to insect stings, 2749  
 intermediate-type, 2115  
 pathophysiology of, 2115–2116  
 to transfusions, 138e-5
- Hypersensitivity vasculitis, 2191
- Hypersplenism, 411, 2064
- Hypertension, **1611**  
 after kidney transplantation, 1831  
 after stroke, 1627  
 approach to the patient, 1621–1622  
 deaths from, by sex, 6e-1t  
 definition of, 1616, 1616t  
 in diabetes mellitus, 2426, 2428  
 diagnosis of, 1621–1622, 1621t  
 diet and, 95e-5  
 ECG in, 269e-15f  
 epidemiology of, 1611–1612  
 genetic considerations in, 1612, 1620t  
 global considerations in, 266e-4  
 high-altitude travel and, 476e-5  
 history in, 1622, 1622t  
 hypokalemic, 64e-8, 307, 1618, 2319  
 isolated systolic, 1616, 1616t  
 laboratory evaluation of, 1622, 1622t  
 malignant. *See* Malignant hypertension  
 mechanisms of  
 arterial pressure, 1612, 1612f  
 autonomic nervous system, 1613  
 intravascular volume, 1612–1613  
 renin-angiotensin-aldosterone system, 1613–1614, 1614f  
 vascular, 1614–1615  
 in metabolic syndrome, 291e-6, 1617, 2451–2452, 2454
- mineralocorticoid-mediated, 64e-8, 1614  
 monogenic, 1620–1621, 1620t, 1621f  
 obesity and, 1617  
 oral contraceptives and, 2391t  
 in paraganglioma, 1620  
 paraneoplastic, 609t  
 pathologic consequences of, **1615**  
 cardiovascular, 266e-4, 291e-6, 1587  
 cognitive dysfunction, 1615  
 erectile dysfunction, 326  
 heart failure, 1501, 1615. *See also* Heart failure (HF)  
 peripheral artery disease, 1616  
 renal, 62e-9f, 289t, 1615–1616, 1835t, 1847–1848  
 stroke, 1615, 1627, 2582–2583, 2583t. *See also* Intracranial hemorrhage  
 physical examination in, 201, 201f, 1444–1445, 1616, 1621–1622  
 portal. *See* Portal hypertension  
 in pregnancy, 45–46, 1620t, 1621  
 primary (essential), 46, 1616–1617  
 progesterone-induced, 2318t  
 pulmonary arterial. *See* Pulmonary arterial hypertension (PAH)  
 racial differences in complications of, 1612  
 resistant, 1626  
 risk factors for, 1612  
 screening for, 29t  
 secondary  
 in acromegaly, 1620  
 in aldosteronism, 1614, 1618–1619  
 in coarctation of the aorta, 1620  
 in Cushing's syndrome, 1619  
 drug-induced, 1617t  
 etiology of, 1617t  
 in pheochromocytoma, 1613, 1619, 2329  
 in renal disease, 1617  
 in renovascular disease, 1617–1618  
 in sleep apnea, 1619–1620  
 in thyroid disease, 1620  
 sodium intake and, 1612  
 stroke and, 2567t  
 supine, 146  
 systolic with wide pulse pressure, 1616  
 treatment of, **1622**  
 ACE inhibitors, 1623, 1623t, 1625  
 aldosterone antagonists, 1623, 1623t  
 alpha blockers, 1623t, 1624  
 ARBs, 1623, 1623t, 1625  
 beta blockers, 1623t, 1624–1625  
 blood pressure goals in, 1626  
 calcium channel blockers, 1624t, 1625  
 carotid sinus stimulation, 1625–1626  
 catheter-based renal denervation for, 296e-5  
 in chronic kidney disease, 1817  
 in diabetes mellitus, 2428  
 diuretics, 1623, 1623t, 1625  
 lifestyle modifications, 1622–1623, 1622t  
 in metabolic syndrome, 2454  
 in polycystic kidney disease, 1853  
 renal denervation, 1625–1626  
 selection of, 1625–1626  
 sympatholytics, 1623t, 1625  
 vasodilators, 1623t, 1625  
 in urinary tract obstruction, 1873  
 vasoconstrictor use in, 242  
 white coat, 1445, 1616  
 in women, 6e-1t, 6e-4
- Hypertensive emergencies, 1626–1627, 1626t, 1627t. *See also* Malignant hypertension
- Hypertensive encephalopathy, 1615, 1626–1627, 2584
- Hyperthermia, 124, 138. *See also* Heat-related illness
- Hyperthyroidism  
 clinical features of, 152  
 alopecia, 355  
 cardiac, 290e-1t, 290e-2, 1563  
 cutaneous, 360, 363  
 diarrhea, 855t  
 edema, 253  
 hypercalcemia, 2478  
 hypertension, 1620